DM Clinical Research Launches Inaugural Advisory Board
Today, DM Clinical Research, a prominent network specializing in multi-therapeutic clinical trials, has announced the creation of its first-ever Advisory Board. This board consists of esteemed professionals from the realms of clinical research and healthcare, tasked with providing essential strategic guidance to the Executive Leadership Team during this transformative phase.
Strategic Growth and Expert Insights
CEO Mohammad Millwala expressed pride in this new initiative, stating, "We are honored to partner with such distinguished leaders. As we embark on this exciting growth journey, our leadership is focused on maintaining a data-driven approach. The insights and connections that the Advisory Board brings will be vital for our responsible scaling and commitment to patient-centered research."
Notable Board Members
The Advisory Board is composed of influential figures such as Kushal Gohil, who serves as the Senior Vice President of Global Project Leadership & Launch Excellence at Parexel. Gohil is recognized for his extensive experience in the Contract Research Organization (CRO) space, where he has successfully managed large-scale projects that encompass operations, corporate strategy, and sales operations. His academic credentials include an MBA from MIT Sloan, a Bachelor of Pharmacy, and advanced degrees in Drug Development and Marketing.
Commitment to Patients and Sites
Upon joining the Advisory Board, Gohil remarked, "I am honored to be part of DM Clinical Research's inaugural Advisory Board. The focus on patients and sites is essential for the success of clinical trials, and I look forward to contributing to DM Clinical's mission of offering innovative solutions that prioritize patient welfare, empower sites, and encourage significant advancements in the field of clinical research."
About DM Clinical Research
DM Clinical Research operates as a national network of integrated multi-therapeutic clinical trial sites, headquartered in Houston, Texas. Established in 2006, the organization includes more than 35 research centers, alongside physician practices embedded in various therapeutic areas across the country. DM Clinical Research has earned recognition such as the 2024 Society for Clinical Research Sites Site Spark Award and the esteemed 2023 Best Clinical Trial Network Award by World Vaccine Congress.
Advancing Research and Community Involvement
Through strategic partnerships with noted global pharmaceutical sponsors, DM Clinical Research is dedicated to providing local communities with opportunities to engage in pioneering research under the supervision of qualified medical professionals. This collaboration ensures that patients have access to innovative treatments and clinical advancements.
Frequently Asked Questions
What is the purpose of the new Advisory Board?
The Advisory Board aims to offer strategic guidance on growth priorities and operational excellence to DM Clinical Research.
Who are the notable members of the Advisory Board?
Kushal Gohil, an experienced leader from Parexel, is one of the highlighted members of the Advisory Board.
What is DM Clinical Research known for?
DM Clinical Research is recognized for its extensive multi-therapeutic clinical trial sites and commitment to patient-centered research.
When was DM Clinical Research founded?
DM Clinical Research was founded in 2006 and has since grown significantly.
How can interested parties learn more about DM Clinical Research?
For more information, interested individuals can visit the DM Clinical Research website or contact them directly.
